State Street’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

State Street’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,177	Closed	-$38.4K	–	4798
2023 Q1	$38.4K	Hold	3,177	–	–	﹤0.01%	4569
2022 Q4	$14.5K	Hold	3,177	–	–	﹤0.01%	4771
2022 Q3	$21K	Sell	3,177 -2,500	-44%	-$22.8K	﹤0.01%	4830
2022 Q2	$61K	Sell	5,677 -19,744	-78%	-$265K	﹤0.01%	4685
2022 Q1	$486K	Buy	25,421 +5,359	+27%	+$119K	﹤0.01%	4059
2021 Q4	$720K	Buy	20,062 +2,622	+15%	+$149K	﹤0.01%	3895
2021 Q3	$1.28M	Buy	17,440 +7,561	+77%	+$582K	﹤0.01%	3732
2021 Q2	$1.38M	Buy	9,879 +4,007	+68%	+$704K	﹤0.01%	3612
2021 Q1	$1.71M	Buy	+5,872	New	+$2.33M	﹤0.01%	3496

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street's SGTX Position: Q2 2023 in Review

State Street sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 3,177 shares — an estimated $38.4K sold.

State Street first reported a position in SGTX in Q1 2021 and held it in 9 quarters. The position peaked at $1.71M in Q1 2021. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

State Street reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
State Street sold 3,177 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $38.4K.
State Street first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
State Street's Sigilon Therapeutics, Inc. Common Stock position peaked at $1.71M in Q1 2021.
16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.